Corcept Therapeutics

(NASDAQ) CORT

Current Price$46.60

Market Cap$5.00B

Since IPO (2004)+281%

5 Year+99%

1 Year-34%

1 Month+24%

Corcept Therapeutics Financials at a Glance

Market Cap

$5.00B

Revenue (TTM)

$761.41M

Net Income (TTM)

$99.08M

EPS (TTM)

$0.82

P/E Ratio

56.99

Dividend

$0.00

Beta (Volatility)

1.00 (Low)

Dividend

$0.00

Beta (Volatility)

1.00 (Low)

Price

$46.60

Volume

Open

$46.22

Price

$46.60

Volume

Open

$46.22

Previous Close

$46.62

Daily Range

$45.98 - $47.09

52-Week Range

$28.66 - $91.00

Dividend

$0.00

Beta (Volatility)

1.00 (Low)

Price

$46.60

Volume

Open

$46.22

Previous Close

$46.62

Daily Range

$45.98 - $47.09

52-Week Range

$28.66 - $91.00

CORT News

Two people participating in a telehealth session

Page 1

CORT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Corcept Therapeutics

Industry

Pharmaceuticals

Sector

Health Care

Employees

730

CEO

Joseph K. Belanoff, MD

Website

www.corcept.com

Headquarters

Menlo Park, CA 94025, US

CORT Financials

Key Financial Metrics (TTM)

Gross Margin

98%

Operating Margin

Net Income Margin

13%

Return on Equity

15%

Return on Capital

Return on Assets

12%

Earnings Yield

1.75%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.00B

Shares Outstanding

107.36M

Volume

Avg. Volume

1.72M

Financials (TTM)

Gross Profit

$748.43M

Operating Income

$44.80M

EBITDA

$68.35M

Operating Cash Flow

$142.00M

Capital Expenditure

$211.00K

Free Cash Flow

$141.78M

Cash & ST Invst.

$372.15M

Total Debt

$6.11M

Corcept Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$202.13M

+11.1%

Gross Profit

$199.58M

+11.5%

Gross Margin

98.74%

N/A

Market Cap

$5.00B

N/A

Market Cap/Employee

$10.01M

N/A

Employees

500

N/A

Net Income

$24.29M

-20.1%

EBITDA

$10.39M

-59.6%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$366.05M

-2.8%

Accounts Receivable

$59.79M

+2.9%

Inventory

$12.87M

+3.7%

Long Term Debt

$5.02M

-17.8%

Short Term Debt

$1.08M

+30.8%

Return on Assets

11.84%

N/A

Return on Invested Capital

6.68%

N/A

Free Cash Flow

$38.40M

-35.1%

Operating Cash Flow

$38.45M

-35.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CAICaris Life Sciences, Inc.

CAICaris Life Sciences, Inc.$18.44-7.48%

RYTMRhythm Pharmaceuticals, Inc.

RYTMRhythm Pharmaceuticals, Inc.$84.18-1.20%

MRUSMerus N.V.

MRUSMerus N.V.$90.00+0.00%

ABVXAbivax S.A.

ABVXAbivax S.A.$109.87-1.81%

NUVLNuvalent, Inc.

NUVLNuvalent, Inc.$101.94-2.02%

CYTKCytokinetics, Incorporated

CYTKCytokinetics, Incorporated$60.69-1.48%

HALOHalozyme Therapeutics, Inc.

HALOHalozyme Therapeutics, Inc.$63.86-0.98%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$213.48-0.01%

INTCIntel

INTCIntel$84.52-0.01%

NOKNokia

NOKNokia$11.30+0.05%

TSLATesla

TSLATesla$376.32-0.01%

JOBYJoby Aviation

JOBYJoby Aviation$8.91-0.01%

MUMicron Technology

MUMicron Technology$504.51-0.04%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$54.05+0.03%

Questions About CORT

What is the current price of Corcept Therapeutics?

Corcept Therapeutics is trading at $46.62 per share.

What is the 52-week range for Corcept Therapeutics?

Over the past 52 weeks, Corcept Therapeutics has traded between $28.66 and $91.00.

How much debt does Corcept Therapeutics have?

As of the most recent reporting period, Corcept Therapeutics reported total debt of $6.11M.

How much cash does Corcept Therapeutics have on hand?

Corcept Therapeutics reported $120.50M in cash and cash equivalents in its most recent financial results.

What is Corcept Therapeutics’s dividend yield?

Corcept Therapeutics does not currently have a dividend yield.

Corcept Therapeutics

Corcept Therapeutics Financials at a Glance

CORT News

Why Corcept Therapeutics Zoomed Nearly 9% Higher This Week

Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday

Corcept Insider Transaction Explained After Shares Tumble 50% in One Day

Why Corcept Therapeutics Plummeted by 50% Today

3 Reasons Why Corcept Therapeutics Is a Better Buy Than Shiba Inu Coin

Why Corcept Therapeutics Stock Was Up 11.6% Friday

Why Corcept Therapeutics Tanked by Almost 17% Today

3 Healthcare Stocks That Could Be Millionaire-Makers

CORT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Corcept Therapeutics

CORT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Corcept Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CORT

What is the current price of Corcept Therapeutics?

What is the 52-week range for Corcept Therapeutics?

How much debt does Corcept Therapeutics have?

How much cash does Corcept Therapeutics have on hand?

What is Corcept Therapeutics’s dividend yield?

Premium Investing Services